Sam Murphy

Chief Executive Officer Salubris Bio

Sam is currently CEO of SalubrisBio and has worked at SalubrisBio since 2017. Prior to joining SalubrisBio, Sam worked for more than ten years in strategy consulting and transaction advisory services across several global firms, most recently as a Senior Principal at IMS (now IQVIA). Sam’s commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, as well as numerous small and mid-sized biotech companies, with an emphasis on business development and market access. Sam completed his PhD in Virology at the University of Pennsylvania and his Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at Children’s Hospital of Philadelphia. Sam currently also serves as Chairman of the Board at GO Therapeutics, and a Board Observer at Mercator Medsystems. Sam was previously Board Director at MedAlliance SA (acquired for up to $1.1B by Cordis) and Viracta Therapeutics (public by reverse merger VIRX). He is an author of >20 peer-reviewed publications and an inventor on several issued patents.

Seminars

Tuesday 24th February 2026
Detailing Translational Development & Clinical Dose Escalation of JK06: A 5T4-Directed Biparatopic ADC
2:30 pm
  • Detailing clinical dose escalation activity of biparatopic ADC JK06 across efficacy, safety and PK data
  • Contrasting emerging JK06 clinical profile versus anticipated results from the preclinical characterisation
  • Explaining the potential of quadrivalent biparatopic ADCs to deliver differentiated clinical performance versus classical ADC design
Sam Murphy Speaker Photo - 16th World ADC London Summit